

2004 Current Fiscal Year Report: Department of Defense Pharmacy and Therapeutics Committee

Report Run Date: 04/26/2024 10:42:51 PM

1. Department or Agency

Department of Defense

2. Fiscal Year

2004

3. Committee or Subcommittee

Department of Defense Pharmacy and
Therapeutics Committee

3b. GSA

Committee

No.

9482

4. Is this New During Fiscal Year?

No

5. Current Charter

05/30/2002

6. Expected Renewal Date

7. Expected Term Date

8a. Was Terminated During FiscalYear?

Yes

8b. Specific Termination Authority

8c. Actual Term Date

09/30/2004

9. Agency Recommendation for Next FiscalYear

Terminate

10a. Legislation Req to Terminate?

10b. Legislation Pending?

11. Establishment Authority Statutory (Congress Created)

12. Specific Establishment Authority

13. Effective Date

14. Committee Type

Continuing

14c. Presidential?

No

15. Description of Committee Other Committee

16a. Total Number of Reports

No Reports for
this FiscalYear

17a. Open

0 17b. Closed0 17c. Partially Closed0 Other Activities0 17d. Total0

Meetings and Dates

No Meetings

Current Next
FY FY

18a(1). Personnel Pmts to Non-Federal Members	\$0.00	\$0.00
18a(2). Personnel Pmts to Federal Members	\$0.00	\$0.00
18a(3). Personnel Pmts to Federal Staff	\$0.00	\$0.00
18a(4). Personnel Pmts to Non-Member Consultants	\$0.00	\$0.00
18b(1). Travel and Per Diem to Non-Federal Members	\$0.00	\$0.00
18b(2). Travel and Per Diem to Federal Members	\$0.00	\$0.00
18b(3). Travel and Per Diem to Federal Staff	\$0.00	\$0.00
18b(4). Travel and Per Diem to Non-member Consultants	\$0.00	\$0.00
18c. Other(rents,user charges, graphics, printing, mail, etc.)	\$0.00	\$0.00
18d. Total	\$0.00	\$0.00
19. Federal Staff Support Years (FTE)	0.00	0.00

20a. How does the Committee accomplish its purpose?

Created by the National Defense Authorization Act, this committee is tasked with developing a uniform formulary of pharmaceutical agents, review such formulary on a periodic basis, and make additional recommendations as necessary . The committee is responsible for encouraging the use of safe, effective pharmaceutical agents that will produce the desired outcomes of drug therapy at a reasonable cost to DoD. The committee will 1) consider the relative safety, effectiveness, cost, and other pertinent factors in deciding which pharmaceutical agents are included on the uniform formulary and the Basic Core Formulary (BCF - applies only to Military Treatment Facilities); 2) conduct therapeutic drug class reviews on a

scheduled basis; 3) evaluate requests for changes to the uniform formulary and the BCF within the Military Health System.

20b. How does the Committee balance its membership?

All 22 voting members and additional non-voting members will have expertise in identifying the medical and pharmaceutical needs of the population served throughout the Military Health System. There will be representatives from all the services, physicians, pharmacists, TRICARE providers, contracting experts

20c. How frequent and relevant are the Committee Meetings?

This committee is expected to meet four times per year, once underway.

20d. Why can't the advice or information this committee provides be obtained elsewhere?

Required by Public Law 106-65, section 701 (amends 10USC Chapter 55 by inserting a new section 1074g, entitled Pharmacy Benefits Program.)

20e. Why is it necessary to close and/or partially closed committee meetings?

Meetings will need to be closed due to discussion of proprietary information and procurement sensitive costing information.

21. Remarks

The FY00 National Defense Authorization Act established this committee under the Federal Advisory Committee Act. Subsequently, the FY04 National Defense Authorization Act removed all non-government employees from the committee, hence eliminating it as a FACA Committee.

Designated Federal Officer

James H Young Director, DoD Pharmacy
Programs

Narrative Description

The DoD Pharmacy and Therapeutics Committee was established in the National Defense Authorization Act of FY2000 to make formulary recommendations to the Assistant Secretary of Defense. As of Nov 2004, the Committee has never met and was subsequently terminated in the National Defense Authorization Act of FY2005.

What are the most significant program outcomes associated with this committee?

Checked if
Applies

Improvements to health or safety	<input type="checkbox"/>
Trust in government	<input type="checkbox"/>
Major policy changes	<input type="checkbox"/>
Advance in scientific research	<input type="checkbox"/>
Effective grant making	<input type="checkbox"/>
Improved service delivery	<input type="checkbox"/>
Increased customer satisfaction	<input type="checkbox"/>
Implementation of laws or regulatory requirements	<input type="checkbox"/>
Other	<input checked="" type="checkbox"/>

Outcome Comments

Committee was removed from FACA status prior to ever having a meeting.

What are the cost savings associated with this committee?

Checked if Applies

None	<input type="checkbox"/>
Unable to Determine	<input type="checkbox"/>
Under \$100,000	<input type="checkbox"/>

\$100,000 - \$500,000	<input type="checkbox"/>
\$500,001 - \$1,000,000	<input type="checkbox"/>
\$1,000,001 - \$5,000,000	<input type="checkbox"/>
\$5,000,001 - \$10,000,000	<input type="checkbox"/>
Over \$10,000,000	<input type="checkbox"/>
Cost Savings Other	<input type="checkbox"/>

Cost Savings Comments

NA

What is the approximate Number of recommendations produced by this committee for the life of the committee?

0

Number of Recommendations Comments

NA

What is the approximate Percentage of these recommendations that have been or will be Fully implemented by the agency?

0%

% of Recommendations Fully Implemented Comments

NA

What is the approximate Percentage of these recommendations that have been or will be Partially implemented by the agency?

0%

% of Recommendations Partially Implemented Comments

NA

Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered?

Yes ☐ No ☒ Not Applicable ☐

Agency Feedback Comments

NA

What other actions has the agency taken as a result of the committee's advice or recommendation?

Checked if Applies

- | | |
|-----------------------------------|--------------------------|
| Reorganized Priorities | <input type="checkbox"/> |
| Reallocated resources | <input type="checkbox"/> |
| Issued new regulation | <input type="checkbox"/> |
| Proposed legislation | <input type="checkbox"/> |
| Approved grants or other payments | <input type="checkbox"/> |
| Other | <input type="checkbox"/> |

Action Comments

NA

Is the Committee engaged in the review of applications for grants?

No

Grant Review Comments

NA

How is access provided to the information for the Committee's documentation?

Checked if Applies

- | | |
|---------------------------|-------------------------------------|
| Contact DFO | <input type="checkbox"/> |
| Online Agency Web Site | <input type="checkbox"/> |
| Online Committee Web Site | <input type="checkbox"/> |
| Online GSA FACA Web Site | <input type="checkbox"/> |
| Publications | <input type="checkbox"/> |
| Other | <input checked="" type="checkbox"/> |

Access Comments

There is no Committee documentation since the Committee never met. The DFO can answer any questions regarding this issue